Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis
NCT ID: NCT01979926
Last Updated: 2014-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
102 participants
INTERVENTIONAL
2013-11-30
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
N02RS1 200mg
Combination of Broussonetia spp and Lonicera spp
Combination of Broussonetia spp and Lonicera spp
600 mg/ day or 1200 mg/ day for 7 days
N02RS1 400mg
Combination of Broussonetia spp and Lonicera spp
Combination of Broussonetia spp and Lonicera spp
600 mg/ day or 1200 mg/ day for 7 days
Placebo
Sugar pill
Combination of Broussonetia spp and Lonicera spp
600 mg/ day or 1200 mg/ day for 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combination of Broussonetia spp and Lonicera spp
600 mg/ day or 1200 mg/ day for 7 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients Acute and Chronic Bronchitis
Exclusion Criteria
* Patients who need treatments of antibiotic and acute bronchitis infection.
* Patients who have gotten teatments of antibiotic,bronchodilator,painkiller and secretagog within 7 days.
* Bronchial asthma patient.
* Patients who have an indication of bleeding.
* Patients who have a serious heart and renal disease or liver ailment or immunosuppressive response.
* Patients who have history of over 3 phage of Chronic obstructiv lung disease
* Bronchiectasis patients.
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PharmaKing
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wayne B An, Bs
Role: STUDY_DIRECTOR
Korea Pharmaceutical Manufacturers Association
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul Nat'l University of Boramae Hospital
Seoul, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMK-N02RS1
Identifier Type: -
Identifier Source: org_study_id